Table 4.
Follow up data as of January, 2011
| NORMAL(N=35) | BORDERLINE(N=28) | |
|---|---|---|
| Follow up period, months, mean(SD) | 26.53(15.48) | 24.69(17.72) |
| Repeat RHC | 13 | 11 |
| Time to repeat RHC, months, mean(SD) | 14.92(9.23) | 12.19(6.82) |
| Results | ||
| Normal | 4 | 2 |
| Exercise mPAP>30mmHg | 5 | 4 |
| Resting PH | ||
| PAH | 3 | 3 |
| PVH | 0 | 2 |
| PH-ILD | 1 | 1§ |
| Complications | ||
| PH-related | ||
| Lung transplant | 2 | 1 |
| Right sided heart failure | 2 | 0 |
| Non PH-related | ||
| Left heart failure | 1 | 0 |
| Myelodysplastic syndrome | 1 | 0 |
| Lung cancer | 1 | 0 |
| Severe restrictive lung disease | 0 | 2 |
| Death | ||
| Due to PH complications | 1(Right heart failure) | 2(severe PAH, transplant) |
| Due to non PH complications | 1(lung cancer) | 1(ILD) |
| Reason unknown | 1 | 1 |
| Lost to follow up | 5 | 2 |
| PH specific medications(overall / for PH only) | ||
| Endothelin receptor antagonists | 6/5 | 15/14 |
| Phosphodiesterase inhibitors | 5/4 | 8/7 |
| Prostacyclin | 2/2 | 1/1 |
| Combinations of the above | 1/1 | 5/5 |
| Other medications | ||
| Immunosuppressives | 4† | 2‡ |
| Nasal O2 | 3 | 9 |
| NYHA class at followup | ||
| 1= Dyspnea with extreme activity | 8 | 8 |
| 2= Dyspnea with moderate activity | 14 | 9 |
| 3= Dyspnea with minimal activity | 5 | 6 |
| 4= Dyspnea at rest | 0 | 1 |
| General health status at followup | ||
| Well/Same | 25 | 18 |
| Worse | 5 | 7 |
| Lost follow up/unknown | 5 | 3 |
PAH= pulmonary arterial hypertension, PVH= pulmonary venous hypertension, ILD= interstitial lung disease
§
1 patient was diagnosed with severe PH-ILD on repeat echocardiogram
†
1 on mycophenolate mofetil, 1 on azathioprine, 1 on cyclophosphamide, 1 on transplant rejection prevention medications
‡
1 on rituximab, 1 on mycophenolate mofetil